For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

Ashland Inc. (ASH) recorded third-quarter fiscal 2024 (ended Jun 30, 2024) adjusted earnings of $1.49 per share, up from $1.23 in the prior-year quarter. The bottom line surpassed the Zacks Consensus Estimate of $1.47.Sales were down 0.4% year over year to $544 million. The top line missed the Zacks Consensus Estimate of $569 million. Higher volumes within the Personal Care and Specialty Additives segments were partly offset by reduced Life Sciences volumes. Pricing was weaker than the prior-year quarter.Se ...

For the quarter ended June 2024, Ashland (ASH) reported revenue of $544 million, down 0.4% over the same period last year. EPS came in at $1.49, compared to $1.23 in the year-ago quarter.The reported revenue represents a surprise of -4.40% over the Zacks Consensus Estimate of $569.02 million. With the consensus EPS estimate being $1.47, the EPS surprise was +1.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next ...

Ashland (ASH) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.36%. A quarter ago, it was expected that this chemical company would post earnings of $1.19 per share when it actually produced earnings of $1.27, delivering a surprise of 6.72%.Over the last four quarters, the company ha ...

财务业绩 - 销售额为5.44亿美元[2] - 净收益(包括已终止经营业务)为600万美元，每股摊薄收益为0.12美元[2] - 持续经营业务收益为3100万美元，每股摊薄收益为0.60美元[2] - 不包括无形资产摊销费用的经调整持续经营业务收益为7500万美元，每股摊薄收益为1.49美元[2] - 经调整EBITDA为1.39亿美元，较上年同期增长5%[2] - 经营活动产生的现金流为1.28亿美元；持续自由现金流为1.12亿美元[2] - 第三季度销售额为15.91亿美元,较上年同期增长5.4%[46][50] - 第三季度毛利率为27.9%,较上年同期下降3.6个百分点[47] - 第三季度营业亏损为5700万美元,主要由于特殊项目损失[51] - 公司营业收入为42亿美元[72] - 公司调整后营业利润为87亿美元[79] - 公司调整后净利润为60亿美元[80] - 公司自由现金流为99亿美元[76] - 公司调整后EBITDA为139亿美元[77] - 公司营业现金流转换率为2133%[78] - 公司持续自由现金流转换率为81%[78] 业务分部表现 - 个人护理和专业添加剂分部销售额分别增长20%和下降1%[14,16] - 生命科学业务调整后EBITDA为59百万美元，较上年同期下降18.1%[64] - 个人护理业务调整后EBITDA为51百万美元，较上年同期增长45.7%[65] - 特殊添加剂业务调整后EBITDA为38百万美元，较上年同期增长31.0%[66] - 中间体业务调整后EBITDA为9百万美元，较上年同期下降43.8%[67] 特殊项目 - 公司计提了99百万美元的营养品资产减值损失[70] - 公司计提了35百万美元的环境准备金调整[70] - 公司计提了8百万美元的加速折旧费用[68,70] - 公司计提了9900万美元的Nutraceutical业务减值[80] - 公司计提了5600万美元的加速折旧[80] - 公司计提了4100万美元的环境准备金[80] 每股收益 - 公司三个月和九个月期间的持续经营业务的摊薄每股收益分别为0.79美元和3.53美元[82] - 公司三个月和九个月期间的关键项目税前影响分别为0.10美元和3.81美元[82] - 公司三个月和九个月期间的关键项目税后影响分别为0.16美元和3.33美元[82] - 公司三个月和九个月期间的税务相关关键项目影响分别为-0.08美元和-4.61美元[82] - 公司三个月和九个月期间的调整后持续经营业务摊薄每股收益分别为0.87美元和2.25美元[82] - 公司三个月和九个月期间的不包括无形资产摊销费用的调整后持续经营业务摊薄每股收益分别为1.23美元和3.19美元[82] - 公司三个月和九个月期间的无形资产摊销费用(税后)影响分别为0.36美元和0.94美元[82,83] 其他 - 回购了130万股股票；现有授权下还剩7.7亿美元[2,6] - 公司预计第四季度销售额为5.3亿美元至5.4亿美元，经调整EBITDA为1.3亿美元至1.4亿美元[25] - 全年预计销售额约为21亿美元，经调整EBITDA为4.65亿美元至4.75亿美元[25] - 公司在第四财季的非GAAP财务指标指引范围无法与GAAP财务指标进行量化调和[38] - 公司主要从事添加剂和特殊成分业务,服务于多个消费和工业市场[39] - 公司预计未来可能面临的风险包括收购和剥离活动、大量债务、自然灾害、网络事件等[41][42] - 截至2024年6月30日,公司现金及现金等价物余额为3.99亿美元[53] - 截至2024年6月30日,公司总资产为57.47亿美元,较2023年9月30日减少3.2%[52][53][56] - 截至2024年6月30日,公司总负债为27.80亿美元,较2023年9月30日减少2.4%[58][59] - 截至2024年6月30日,公司股东权益为29.67亿美元,较2023年9月30日减少4.2%[60] - 公司净收入为6百万美元，较上年同期下降88.0%[61] - 公司营业利润为-61百万美元，较上年同期下降146.9%[70] - 公司调整后EBITDA为139百万美元，较上年同期增长4.5%[63]

Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased 1.3 million ...

Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased 1.3 million ...

Investors might want to bet on Ashland (ASH) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of Ashland (ASH) and Novozymes A/S (NVZMY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy tha ...

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Ashland (ASH) or Novozymes A/S (NVZMY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes compa ...